Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Katsutoshi Hiramatsu"'
Autor:
Katsutoshi Hiramatsu, Hideki Maeda
Publikováno v:
Clinical and Translational Science, Vol 17, Iss 5, Pp n/a-n/a (2024)
Abstract No systematic review of trial designs in patients with relapsing multiple sclerosis (RMS) was reported. This systematic review was conducted on the trial designs and primary end points (PEs) of phase II and III trials intended to modify the
Externí odkaz:
https://doaj.org/article/4fdcda9fd08c46218adc12121540ec05
Autor:
Tamio Teramoto, Tomohiro Sawa, Satoshi Iimuro, Hyoe Inomata, Takashi Koshimizu, Iori Sakakibara, Katsutoshi Hiramatsu
Publikováno v:
Cardiovascular Therapeutics, Vol 2020 (2020)
Background. Familial hypercholesterolemia (FH) is a genetic disorder characterized by high levels of low-density lipoprotein cholesterol (LDL-C). Because of underdiagnosis, acute coronary syndrome (ACS) is often the first clinical manifestation of FH
Externí odkaz:
https://doaj.org/article/2d059acdfb334e55bfa23834a38283b5
Autor:
Mitsunori Sugiyama, Kazuyuki Shimada, Kazuhito Shiosakai, Katsutoshi Hiramatsu, Masayuki Shirayama, Kazuomi Kario
Publikováno v:
Pharmaceuticals, Vol 3, Iss 1, Pp 225-236 (2010)
Background: Morning blood pressure (BP) surge, which exhibits an age-related increase, is a risk factor for stroke in elderly hypertensive patients, independently of the 24-h BP level. We studied the effect of the new baroreceptor sensitivity (BRS)-r
Externí odkaz:
https://doaj.org/article/0ba7d3a744504126bd92b462468fc7a8
Publikováno v:
Drugs-Real World Outcomes
The aim of this article is to help develop a common understanding of the current status, challenges, and future perspectives of real-world data (RWD) and real-world evidence (RWE) in Japan. RWD and RWE are very widely used terms, but standardized def
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d04ee929065c5dfdfe44678b6b6596d
https://doi.org/10.1007/s40801-021-00266-3
https://doi.org/10.1007/s40801-021-00266-3
Autor:
Masaaki Niino, J. Yun, André Matta, Masakazu Hase, Shinichi Torii, Yasuhiro Onizuka, Hirofumi Ochi, Katsutoshi Hiramatsu
Publikováno v:
Advances in Therapy
Introduction The long-term safety of dimethyl fumarate (DMF) in patients with relapsing-remitting multiple sclerosis (RRMS) has been studied in mainly Caucasian patients. The present interim analysis aimed to evaluate the 72-week safety of DMF in Jap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4477070f661d8c0b03d520cf831d1de7
https://doi.org/10.1007/s12325-018-0788-8
https://doi.org/10.1007/s12325-018-0788-8
Publikováno v:
Multiple Sclerosis and Demyelinating Disorders, Vol 3, Iss 1, Pp 1-11 (2018)
Background There are few reports about the actual state of diagnosis for multiple sclerosis (MS) in Japan. In addition, in late years multiple disease-modifying drugs (DMDs) were released in Japan, but there are few reports of the actual treatment si
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::324685abb88ccdfb6254fb7e3bcb62f9
http://link.springer.com/article/10.1186/s40893-018-0036-8
http://link.springer.com/article/10.1186/s40893-018-0036-8
Autor:
André Matta, Yasuhiro Onizuka, Shinichi Torii, Takashi Ohashi, Masahiro Mori, Katsutoshi Hiramatsu, J. Yun, Masakazu Hase
Publikováno v:
Multiple Sclerosis Journal-Experimental, Translational and Clinical
Background The use of dimethyl fumarate has not been reported in treatment-naïve Japanese patients with relapsing–remitting multiple sclerosis. Objectives The purpose of this study was to evaluate the efficacy and safety of dimethyl fumarate in tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6d9a51aca3e93806179df7a460e17b2
http://europepmc.org/articles/PMC6558550
http://europepmc.org/articles/PMC6558550
Autor:
Yoshihiro Mori, Katsutoshi Hiramatsu, Yasuyuki Okuda, Shigeru Miyazaki, Tamio Teramoto, Ryuzo Kawamori, Satoshi Teramukai
Publikováno v:
Clinical and Experimental Hypertension. 36:236-243
To identify risk factors for cardiovascular disease (CVD) in hypertensive patients with no history of CVD being treated with antihypertensive drugs, we examined subgroup data (n = 13 052) from the prospective, observational Olmesartan Mega Study to D
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b547597e7e0764bf6cd24e04c950a6e
https://doi.org/10.3109/10641963.2013.810226
https://doi.org/10.3109/10641963.2013.810226
Autor:
Toshio Kushiro, Yusuke Ishikawa, Kazuyuki Shimada, Ikuo Saito, Katsutoshi Hiramatsu, Kazuomi Kario, Fumiaki Kobayashi, Satoshi Teramukai
Publikováno v:
Journal of Human Hypertension
Morning home blood pressure (BP) levels are more closely associated with cardiovascular risk than clinic BP levels. However, control of morning home BP has been worse than that of clinic BP in clinical practice. We examined the effects of olmesartan-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::224bfb2436b3dc3849409cdbb9ed005e
https://doi.org/10.1038/jhh.2013.68
https://doi.org/10.1038/jhh.2013.68
Autor:
Kazuyuki Shimada, Yoshihiro Mori, Ikuo Saito, Kazuomi Kario, Katsutoshi Hiramatsu, Fumiaki Kobayashi, Toshio Kushiro, Satoshi Teramukai
Publikováno v:
Journal of Clinical Hypertension (Greenwich, Conn.)
To investigate the blood pressure (BP)–lowering effect of olmesartan in relation to chronic kidney disease (CKD)–associated sympathetic nerve activity, a subanalysis was performed using data from the first 16 weeks of the Home BP Measurement With
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a1096e1645acaf79284dc7d84bf5808
https://doi.org/10.1111/jch.12132
https://doi.org/10.1111/jch.12132